Advertisement

Intensity-Modulated Radiation Therapy for Clinically Localized Prostate Cancer

  • Marisa A. Kollmeier
  • Michael J. Zelefsky
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

The goal of the following chapter is to discuss the role of intensity-modulated radiation therapy (IMRT) for clinically localized prostate cancer. We review the important aspects of patient selection for this therapeutic modality as well as discuss the relevant published literature on dose escalation. Additionally, a comprehensive review of techniques and delivery of treatment are presented. Finally, we discuss both the potential acute and late toxicities associated with IMRT.

Keywords

Dose Escalation Planning Target Volume Dose Distribution External Beam Radiation Therapy Fiducial Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Akbal C, Tinay I, Simşek F et al (2008) Erectile dysfunction following radiotherapy and brachytherapy for prostate cancer: pathophysiology, prevention and treatment. Int Urol Nephrol 40:355–363PubMedCrossRefGoogle Scholar
  2. Al-Mamgani A, Heemsbergen WD, Peeters ST et al (2009) Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 73:685–691PubMedCrossRefGoogle Scholar
  3. Beckendorf V, Guerif S, Le Prisé E et al (2011) 70 gy versus 80 gy in localized prostate cancer: 5-year results of getug 06 randomized trial. Int J Radiat Oncol Biol Phys 80:1056–1063PubMedCrossRefGoogle Scholar
  4. Cahlon O, Zelefsky MJ, Shippy A et al (2008) Ultra-high dose (86.4 gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 71:330–337PubMedCrossRefGoogle Scholar
  5. Center MM, Jemal A, Lortet-Tieulent J et al (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079–1092PubMedCrossRefGoogle Scholar
  6. Cesaretti JA, Stock RG, Atencio DP et al (2007) A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Int J Radiat Oncol Biol Phys 68:1410–1416PubMedCrossRefGoogle Scholar
  7. De Meerleer GO, Fonteyne VH, Vakaet L et al (2007) Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol 82:160–166PubMedCrossRefGoogle Scholar
  8. De Meerleer GO, Vakaet LA, De Gersem WR et al (2000) Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison. Int J Radiat Oncol Biol Phys 47:639–648PubMedCrossRefGoogle Scholar
  9. Dearnaley DP, Sydes MR, Graham JD et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8:475–487PubMedCrossRefGoogle Scholar
  10. Kedia S, Zippe CD, Agarwal A et al (1999) Treatment of erectile dysfunction with sildenafil citrate (viagra) after radiation therapy for prostate cancer. Urology 54:308–312PubMedCrossRefGoogle Scholar
  11. Kim MM, Hoffman KE, Levy LB et al (2012) Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer 48:1664–1671PubMedCrossRefGoogle Scholar
  12. Kuban DA, Tucker SL, Dong L et al (2008) Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70:67–74PubMedCrossRefGoogle Scholar
  13. Langen KM, Pouliot J, Anezinos C et al (2003) Evaluation of ultrasound-based prostate localization for image-guided radiotherapy. Int J Radiat Oncol Biol Phys 57:635–644PubMedCrossRefGoogle Scholar
  14. Leibel SA, Zelefsky MJ, Kutcher GJ et al (1994) Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: Interim report of a phase 1 dose-escalation study. J Urol 152:1792–1798PubMedGoogle Scholar
  15. Ling CC, Burman C, Chui CS et al (1996) Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation. Int J Radiat Oncol Biol Phys 35:721–730PubMedCrossRefGoogle Scholar
  16. Michalski JM, Bae K, Roach M et al (2010) Long-term toxicity following 3d conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study. Int J Radiat Oncol Biol Phys 76:14–22PubMedCentralPubMedCrossRefGoogle Scholar
  17. Mulhall J, Ahmed A, Parker M et al (2005) The hemodynamics of erectile dysfunction following external beam radiation for prostate cancer. J Sex Med 2:432–437PubMedCrossRefGoogle Scholar
  18. Nguyen PL, Gu X, Lipsitz SR et al (2011) Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 29:1517–1524PubMedCentralPubMedCrossRefGoogle Scholar
  19. Oliai C, Fisher B, Jani A et al (2012) Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis. Int J Radiat Oncol Biol Phys 84:733–740PubMedCrossRefGoogle Scholar
  20. Peeters ST, Heemsbergen WD, Koper PC et al (2006a) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 gy of radiotherapy with 78 gy. J Clin Oncol 24:1990–1996PubMedCrossRefGoogle Scholar
  21. Peeters STH, Heemsbergen WD, Koper PC et al (2006b) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 gy of radiotherapy with 78 gy. J Clin Oncol 24:1990–1996PubMedCrossRefGoogle Scholar
  22. Pinkawa M, Gagel B, Piroth MD et al (2009) Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 55:227–234PubMedCrossRefGoogle Scholar
  23. Pollack A, Hanlon AL, Horwitz EM et al (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64:518–526PubMedCentralPubMedCrossRefGoogle Scholar
  24. Pollack A, Zagars GK, Starkschall G et al (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097–1105PubMedCrossRefGoogle Scholar
  25. Smit WG, Helle PA, van Putten WL et al (1990) Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18:23–29PubMedCrossRefGoogle Scholar
  26. Spratt DE, Pei X, Yamada J et al (2013) Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 85:686–692PubMedCrossRefGoogle Scholar
  27. Teloken PE, Parker M, Mohideen N et al (2009) Predictors of response to sildenafil citrate following radiation therapy for prostate cancer. J Sex Med 6:1135–1140PubMedCrossRefGoogle Scholar
  28. Trichter F, Ennis RD (2003) Prostate localization using transabdominal ultrasound imaging. Int J Radiat Oncol Biol Phys 56:1225–1233PubMedCrossRefGoogle Scholar
  29. Vora SA, Wong WW, Schild SE et al (2007) Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 68:1053–1058PubMedCrossRefGoogle Scholar
  30. Zelefsky MJ, Fuks Z, Happersett L et al (2000) Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55:241–249PubMedCrossRefGoogle Scholar
  31. Zelefsky MJ, Fuks Z, Hunt M et al (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111–1116PubMedCrossRefGoogle Scholar
  32. Zelefsky MJ, Kollmeier M, Cox B et al (2012a) Improved clinical outcomes with high-dose image-guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 84:125–129PubMedCrossRefGoogle Scholar
  33. Zelefsky MJ, Leibel SA, Gaudin PB et al (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41:491–500PubMedCrossRefGoogle Scholar
  34. Zelefsky MJ, Pei X, Teslova T et al (2012b) Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int 110:1696–1701PubMedCrossRefGoogle Scholar
  35. Zietman AL, Bae K, Slater JD et al (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 28:1106–1111PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Radiation OncologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations